Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 1;150(5):393-405.
doi: 10.1093/ajcp/aqy066.

Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study

Affiliations

Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study

Mihai Merzianu et al. Am J Clin Pathol. .

Abstract

Objectives: To assess bone marrow (BM) sampling in academic medical centers.

Methods: Data from 6,374 BM samples obtained in 32 centers in 2001 and 2011, including core length (CL), were analyzed.

Results: BM included a biopsy (BMB; 93%) specimen, aspirate (BMA; 92%) specimen, or both (83%). The median (SD) CL was 12 (8.5) mm, and evaluable marrow was 9 (7.6) mm. Tissue contraction due to processing was 15%. BMB specimens were longer in adults younger than 60 years, men, and bilateral, staging, and baseline samples. Only 4% of BMB and 2% of BMB/BMA samples were deemed inadequate for diagnosis. BM for plasma cell dyscrasias, nonphysician operators, and ancillary studies usage increased, while bilateral sampling decreased over the decade. BM-related quality assurance programs are infrequent.

Conclusions: CL is shorter than recommended and varies with patient age and sex, clinical circumstances, and center experience. While pathologists render diagnoses on most cases irrespective of CL, BMB yield improvement is desirable.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical indications for bone marrow biopsy (A) and rendered pathologic diagnoses (B). CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma.
Figure 2
Figure 2
Changes in bone marrow clinical and laboratory practice between 2001 and 2011 in 32 participating centers.
Figure 3
Figure 3
Overall (A, B) and separate for 2001 and 2011 (C, D) postprocessing and evaluable marrow core length measurements in 32 participating centers (diamond, mean; line, median; bar, range; box, quartiles 1 to 3, values in millimeters).
Figure 3
Figure 3
Overall (A, B) and separate for 2001 and 2011 (C, D) postprocessing and evaluable marrow core length measurements in 32 participating centers (diamond, mean; line, median; bar, range; box, quartiles 1 to 3, values in millimeters).
Figure 4
Figure 4
Distribution of samples involved by lymphoma relative to core biopsy specimen length.

References

    1. Bishop PW, McNally K, Harris M. Audit of bone marrow trephines. J Clin Pathol. 1992;45:1105-1108. - PMC - PubMed
    1. Reid MM, Roald B. Adequacy of bone marrow trephine biopsy specimens in children. J Clin Pathol. 1996;49:226-229. - PMC - PubMed
    1. Lee SH, Erber WN, Porwit A, et al. ; International Council for Standardization in Hematology. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30:349-364. - PubMed
    1. Arber D, Hasserjian RP. Introduction and overview of the classification of myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours. Lyon, France: IARC; 2017:16-27.
    1. NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. Version 3.2018. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed April 13, 2018.